Hoe verhoudt PETQ's PE Ratio zich tot zijn concurrenten?

PETQ is duur op basis van de Price-To-Earnings -ratio ( 69.7 x) vergeleken met het gemiddelde van de peer ( 23.4 x).

Hoe verhoudt PETQ's PE Ratio zich tot andere bedrijven in de US Healthcare industrie?

PETQ is duur op basis van de Price-To-Earnings -ratio ( 69.7 x) vergeleken met het US Healthcare -industriegemiddelde ( 25.7 x).

Wat is PETQ's PE Ratio vergeleken met zijn Fair PE Ratio? Dit is de verwachte PE Ratio, rekening houdend met de verwachte winstgroei van het bedrijf, winstmarges en andere risicofactoren.

PETQ is duur op basis van de Price-To-Earnings Ratio ( 69.7 x) vergeleken met de geschatte Fair Price-To-Earnings Ratio ( 67 x).

Wat is de reële prijs van PETQ als we kijken naar de toekomstige kasstromen? Voor deze schatting gebruiken we een Discounted Cash Flow-model.

Onvoldoende gegevens om de reële waarde van PETQ te berekenen voor waarderingsanalyse.

Wat is de 12-maandsprognose van de analisten en hebben we enig statistisch vertrouwen in het consensuskoersdoel?

De koersdoelstelling is lager dan de huidige aandelenkoers.

PetIQ (Nasdaq:PETQ) - Aandelenkoers, Nieuws & Analyse

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

PETQ Overzicht aandelen

PetIQ, Inc. is actief als bedrijf voor medicatie en welzijn voor huisdieren in de Verenigde Staten en internationaal.

Over het bedrijf

PETQ fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	3/6
Prestaties in het verleden	2/6
Financiële gezondheid	2/6
Dividenden	0/6

Beloningen

De winst zal naar verwachting met 59.98% per jaar groeien

Dit jaar winstgevend geworden

Risicoanalyse

Rentebetalingen worden niet goed gedekt door de winsten

Grote eenmalige posten die de financiële resultaten beïnvloeden

Volatiele aandelenkoers in de afgelopen 3 maanden

PetIQ, Inc. Concurrenten

Patterson Companies

NasdaqGS:PDCO

US$1.9b

Henry Schein

NasdaqGS:HSIC

US$8.6b

Cardinal Health

NYSE:CAH

US$27.4b

Cencora

NYSE:COR

US$45.9b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor PetIQ
Historische aandelenkoersen
Huidige aandelenkoers	US$30.98
52 Week Hoogtepunt	US$31.06
52 Week Laag	US$15.09
Bèta	1.74
11 maand verandering	0.72%
3 maanden verandering	41.53%
1 Jaar Verandering	66.47%
33 jaar verandering	30.61%
5 jaar verandering	25.32%
Verandering sinds IPO	32.85%

Recent nieuws en updates

Does PetIQ (NASDAQ:PETQ) Have A Healthy Balance Sheet?

Aug 14

PetIQ: Attractive Acquisition Offer After Strong Earnings Growth In Q2

Aug 09

Recent updates

PetIQ, Inc. (NASDAQ:PETQ) Stock Rockets 26% But Many Are Still Ignoring The Company

Aug 16

PetIQ (NASDAQ:PETQ) Has A Somewhat Strained Balance Sheet

Aug 10

PetIQ's (NASDAQ:PETQ) Returns On Capital Are Heading Higher

Jun 14

PetIQ (NASDAQ:PETQ) May Have Issues Allocating Its Capital

Feb 11

PetIQ gains 1.84 % on $30M stock repurchase program

Sep 06

PetIQ (NASDAQ:PETQ) Use Of Debt Could Be Considered Risky

Aug 23

Here's What's Concerning About PetIQ's (NASDAQ:PETQ) Returns On Capital

Jul 27

Is PetIQ (NASDAQ:PETQ) Using Too Much Debt?

May 06

There Are Reasons To Feel Uneasy About PetIQ's (NASDAQ:PETQ) Returns On Capital

Apr 02

The Prognosis For PetIQ

Feb 12

PetIQ: Economies Of Scale Will Kick In Eventually

Jan 03

Rendement voor aandeelhouders

	PETQ	US Healthcare	US Markt
7D	0.2%	4.2%	2.3%
1Y	66.5%	6.9%	35.1%

Rendement versus industrie: PETQ overtrof de US Healthcare industrie, die het afgelopen jaar een rendement 6.9 % opleverde.

Rendement versus markt: PETQ overtrof de US markt, die het afgelopen jaar een rendement opleverde van 35.1 %.

Prijsvolatiliteit

Is PETQ's price volatile compared to industry and market?
PETQ volatility
PETQ Average Weekly Movement	13.4%
Healthcare Industry Average Movement	6.9%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	2.9%

Stabiele aandelenkoers: De aandelenkoers van PETQ is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van PETQ is het afgelopen jaar gestegen van 8% naar 13%.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2010	1,527	Cord Christensen	petiq.com

PetIQ, Inc. is actief als bedrijf voor medicatie en welzijn voor huisdieren in de Verenigde Staten en internationaal. Het is actief in twee segmenten, Producten en Diensten. Het bedrijf biedt Rx-geneesmiddelen voor huisdieren aan, waaronder vlooien- en tekenbestrijding, middelen tegen hartworm, artritis-, schildklier-, diabetes- en pijnbehandelingen, antibiotica en andere speciale medicijnen; en ontwikkelt en produceert zijn eigen merkproducten, evenals merkproducten van derden voor honden en katten.

PetIQ, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van PetIQ zich tot de beurswaarde?
PETQ fundamentele statistieken
Marktkapitalisatie	US$926.64m
Inkomsten(TTM)	US$13.19m
Inkomsten(TTM)	US$1.13b

69.7x

Koers/Winstverhouding

0.8x

P/S-verhouding

Is PETQ overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
PETQ resultatenrekening (TTM)
Inkomsten	US$1.13b
Kosten van inkomsten	US$854.90m
Brutowinst	US$279.43m
Overige uitgaven	US$266.23m
Inkomsten	US$13.19m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	0.44
Brutomarge	24.63%
Nettowinstmarge	1.16%
Schuld/Eigen Vermogen Verhouding	170.0%

Hoe presteerde PETQ op de lange termijn?

Bekijk historische prestaties en vergelijking

This company has been acquired

PETQ Overzicht aandelen

Beloningen

Risicoanalyse

PetIQ, Inc. Concurrenten

NasdaqGS:PDCO

US$1.9b

NasdaqGS:HSIC

US$8.6b

NYSE:CAH

US$27.4b

NYSE:COR

US$45.9b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Bansk Group LLC completed the acquisition of PetIQ, Inc. (NasdaqGS:PETQ) from group of sellers.

Does PetIQ (NASDAQ:PETQ) Have A Healthy Balance Sheet?

PetIQ: Attractive Acquisition Offer After Strong Earnings Growth In Q2

Second quarter 2024 earnings released: EPS: US$0.52 (vs US$0.33 in 2Q 2023)

New minor risk - Share price stability

Bansk Group LLC entered into an Agreement and Plan of Merger to acquire PetIQ, Inc. (NasdaqGS:PETQ) for approximately $980 million.

Recent updates

Bansk Group LLC completed the acquisition of PetIQ, Inc. (NasdaqGS:PETQ) from group of sellers.

Does PetIQ (NASDAQ:PETQ) Have A Healthy Balance Sheet?

PetIQ: Attractive Acquisition Offer After Strong Earnings Growth In Q2

Second quarter 2024 earnings released: EPS: US$0.52 (vs US$0.33 in 2Q 2023)

New minor risk - Share price stability

Bansk Group LLC entered into an Agreement and Plan of Merger to acquire PetIQ, Inc. (NasdaqGS:PETQ) for approximately $980 million.

Price target increased by 8.3% to US$30.33

Bansk Group LLC entered into an Agreement and Plan of Merger to acquire PetIQ, Inc. (NasdaqGS:PETQ) for approximately $980 million.

President & COO exercised options and sold US$483k worth of stock

PetIQ, Inc. to Report Q2, 2024 Results on Aug 07, 2024

PetIQ: Product Margin Gains Offset By Higher Marketing Spend

Insider exercised options and sold US$89k worth of stock

Independent Director recently sold US$269k worth of stock

PetIQ, Inc. Provides Earnings Guidance for the Second Quarter of 2024 and Revised Earnings Guidance for the Full Year 2024

First quarter 2024 earnings released: EPS: US$0.51 (vs US$0.33 in 1Q 2023)

PetIQ, Inc. to Report Q1, 2024 Results on May 08, 2024

PetIQ, Inc., Annual General Meeting, Jun 07, 2024

White Brook Capital - PetIQ: Guidance And Street Estimates Are Too Conservative

PetIQ (NASDAQ:PETQ) Seems To Use Debt Quite Sensibly

PetIQ, Inc. Announces Expansion of Minties Dental Treats Brand with Launch of New Dental Chew for Large-Sized Dogs

Chairman of the Board & CEO exercised options and sold US$362k worth of stock

Full year 2023 earnings released: EPS: US$0.073 (vs US$1.65 loss in FY 2022)

Petiq, Inc. Provides Sales Guidance for the First Quarter and Full Year of 2024

Chairman of the Board & CEO exercised options and sold US$154k worth of stock

PetIQ, Inc. to Report Q4, 2023 Results on Feb 28, 2024

PetIQ: Cost Savings, Higher EBITDA Suggest A Potential Valuation Re-Rate

Chief Financial Officer exercised options and sold US$97k worth of stock

PetIQ, Inc.'s New Sentry™? Portable Calming Diffuser Helps Calm Dogs and Cats During the Busy Holiday Season and Beyond

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: EPS: US$0.015 (vs US$1.68 loss in 3Q 2022)

Petiq, Inc. Provides Earnings Guidance for the Full Year of 2023

PetIQ, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Investors Will Want PetIQ's (NASDAQ:PETQ) Growth In ROCE To Persist

PetIQ, Inc. (NASDAQ:PETQ) Stock Rockets 26% But Many Are Still Ignoring The Company

PetIQ, Inc. Revises Earnings Guidance for the Full Year 2023

PetIQ (NASDAQ:PETQ) Has A Somewhat Strained Balance Sheet

Price target increased by 13% to US$27.50

Petiq, Inc. Announces Termination of R. Michael Herrman, as Executive Vice President and Corporate Secretary

PetIQ, Inc. to Report Q2, 2023 Results on Aug 08, 2023

PetIQ's (NASDAQ:PETQ) Returns On Capital Are Heading Higher

Petiq, Inc. Provides Earnings Guidance for the Second Quarter of 2023 and Reiterates Earnings Guidance for the Full Year 2023

First quarter 2023 earnings released: EPS: US$0.33 (vs US$0.11 in 1Q 2022)

Chairman of the Board & CEO exercised options and sold US$68k worth of stock

Full year 2022 earnings released: US$1.65 loss per share (vs US$0.56 loss in FY 2021)

Price target decreased by 10% to US$21.75

PetIQ (NASDAQ:PETQ) May Have Issues Allocating Its Capital

PetIQ, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Third quarter 2022 earnings released: US$1.68 loss per share (vs US$0.27 loss in 3Q 2021)

Price target decreased to US$24.25

PetIQ, Inc. to Report Q3, 2022 Results on Nov 09, 2022

President & COO recently bought US$97k worth of stock

PetIQ, Inc. (NasdaqGS:PETQ) announces an Equity Buyback for $30 million worth of its shares.

PetIQ gains 1.84 % on $30M stock repurchase program

PetIQ (NASDAQ:PETQ) Use Of Debt Could Be Considered Risky

Second quarter 2022 earnings released: EPS: US$0.16 (vs US$0.14 in 2Q 2021)

PetIQ, Inc. Provides Sales Guidance for the Third Quarter and Full Year 2022

Here's What's Concerning About PetIQ's (NASDAQ:PETQ) Returns On Capital

PetIQ, Inc. to Report Q2, 2022 Results on Aug 09, 2022